内镜鼻窦手术的长期成本效用分析:5年结局分析
本研究基于96例接受内镜鼻窦手术(ESS)的慢性鼻窦炎(CRS)患者与48例匹配药物治疗患者的队列,构建33年时间跨度的Markov决策树经济模型,评估ESS对比单纯药物治疗的长期成本效用。结果显示ESS成本更高但产出更多质量调整生命年(QALY),增量成本效果比(ICER)为4367.68美元/QALY,提示ESS在5年手术结局基础上具有成本效果。
要点
- ESS策略成本63296.10美元,产出22.61 QALY;药物治疗成本26990.27美元,产出13.48 QALY。
- ESS对比单纯药物治疗的ICER为4367.68美元/QALY。
- 基于5年手术结局分析,ESS治疗CRS具有成本效果。
核心结论
- 基于5年手术结局分析,ESS对比单纯药物治疗慢性鼻窦炎患者具有成本效果。
研究设计与样本
- 构建33年时间跨度的队列式Markov决策树经济模型,96例接受ESS的CRS患者与2:1匹配的48例药物治疗患者进行比较。
- 手术队列效用评分来自5年随访的EQ-5D调查,药物管理队列来自1-2年随访。
主要发现
- ESS策略成本63296.10美元,产出22.61 QALY;药物治疗策略成本26990.27美元,产出13.48 QALY。
- ESS对比单纯药物治疗的ICER为4367.68美元/QALY。
关键数值与推荐
- 主要结局指标为增量成本效果比(ICER),即每质量调整生命年的增量成本。
临床怎么用
- 在评估CRS治疗策略时,可将ESS的长期成本效用数据纳入临床决策参考。
局限性
- 证据等级为N/A。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Both endoscopic sinus surgery (ESS) and medical management have shown effectiveness for treatment of chronic rhinosinusitis (CRS); however, the majority of such analyses have relied on short-term surgical outcomes. We aimed to evaluate the long-term (5-year) cost-effectiveness of ESS versus medical management for patients with CRS. METHODS: A cohort-style Markov decision-tree economic model with a 33-year time horizon was developed. A cohort of 96 CRS patients who underwent ESS were compared with a 2 to 1 matched cohort of 48 CRS patients who were treated with medical management at the same academic medical center. Long-term utility scores were calculated from the EuroQol 5-Dimension (EQ-5D) survey at 5-year follow up for the surgical cohort and 1-2 year follow up for the medical management cohort. Decision-tree analysis and a 10-state Markov model utilized published event probabilities and primary data to calculate long-term costs and utility. The primary outcome measure was the incremental cost-effectiveness ratio (ICER), which represents incremental cost per quality-adjusted life year (QALY). RESULTS: The ESS strategy cost more ($63,296.10) but yielded increased QALYs (22.61). In comparison, the medical management strategy cost $26,990.27 but yielded only 13.48 QALYs. The ICER for ESS versus medical therapy alone was $4367.68 per QALY. CONCLUSION: This study shows ESS to be a cost-effective intervention compared to medical therapy alone for the management of patients with CRS based on analysis evaluating long-term (5-year) surgical outcomes. LEVEL OF EVIDENCE: N/A.
引用
- Adams DR, Tashman K, Holbrook EH, et al. Long-Term Cost Utility Analysis of Endoscopic Sinus Surgery: Analysis of 5-Year Outcomes. Laryngoscope. 2025. PMID: 41045102. doi:10.1002/lary.70176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。